产品
编 号：F271392
分子式：C25H25N7O3
分子量：471.51
分子式：C25H25N7O3
分子量：471.51
产品类型
规格
价格
是否有货
1mg
396
In-stock
2mg
600
In-stock
5mg
792
In-stock
10mg
1440
In-stock
50mg
3540
In-stock
100mg
5064
In-stock
结构图
CAS No: 211914-51-1
产品详情
生物活性：
Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM).
体内研究：
Dabigatran (0.01-0.1 mg/kg; i.v.) inhibits clot formation with an ED50 of 0.033 mg/kg in Wessler model.Animal Model:Male rats (Wessler model)
Dosage:0.01, 0.03, 0.05 and 0.1 mg/kg
Administration:Intravenous injection
Result:Inhibited clot formation with an ED50 of 0.033 mg/kg.
体外研究：
Dabigatran (BIBR 953) shows concentration-dependent anticoagulant effects in various species in vitro, doubling the activated partial thromboplastin time (aPTT), prothrombin time (PT) and ecarin clotting time (ECT) in human platelet-poor plasma at concentrations of 0.23, 0.83 and 0.18 μM, respectively.
Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM).
体内研究：
Dabigatran (0.01-0.1 mg/kg; i.v.) inhibits clot formation with an ED50 of 0.033 mg/kg in Wessler model.Animal Model:Male rats (Wessler model)
Dosage:0.01, 0.03, 0.05 and 0.1 mg/kg
Administration:Intravenous injection
Result:Inhibited clot formation with an ED50 of 0.033 mg/kg.
体外研究：
Dabigatran (BIBR 953) shows concentration-dependent anticoagulant effects in various species in vitro, doubling the activated partial thromboplastin time (aPTT), prothrombin time (PT) and ecarin clotting time (ECT) in human platelet-poor plasma at concentrations of 0.23, 0.83 and 0.18 μM, respectively.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备